B+
Bull case
25%
Probability
Target price
$185.00
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
RGEN
RepligenCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The Q2 print showed sequential acceleration, 13% organic growth, stronger adjusted margins, and higher FY26 guidance. Investing.com reported adjusted EPS of $0.54 versus a $0.45 consensus estimate, while Benchmark upgraded the shares to Buy with a $185 target.
Posture
Mixed
Lead driver
Value
What changed
3 setup hits (3d) with net bullish as of 2026-10-25.
What can break
Analyst target breadth and estimate-revision breadth remain limited despite one reported Benchmark upgrade.
Momentum
92
Value
57
Sentiment
43
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $160.00 · Bull $185.00 · Bear $120.00Analysis 2026-07-31; returns require an exact persisted reference.
Earnings
2026-10-27 · BMO
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-31 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bullish
Target $200.33
Why
Momentum92 · Δ7d -4.1
Value57 · Δ7d -0.2
Sentiment43 · Δ7d -0.4
So what
Balanced signals (Net Bullish). Wait for confirmation before sizing up.
Confirming evidence
- • 3 setup hits (3d) with net bullish as of 2026-10-25.
- • Next scheduled catalyst: earnings 2026-10-27 · BMO.
- • Value remains the lead driver in the composite, 7D delta -0.2.
Contradictions & invalidation
- • Analyst target breadth and estimate-revision breadth remain limited despite one reported Benchmark upgrade.
- • BioLife closing and integration may fail to deliver expected growth, margin, or EPS accretion.
- • GAAP EPS declined to $0.09 from $0.26 and GAAP operating income was essentially flat.
Catalyst clock
2026-10-27 · BMO
Q2 beat and raised FY26 guidance support near-term revisions
Lead driver: Value · See fundamentals
Momentum
92
8% active weight
Current posture
7d trendSoftening
Δ7d
-4.1
Δ21d
-3.5
Value
57
47% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.9
Sentiment
43
45% active weight
Current posture
7d trendFlat
Δ7d
-0.4
Δ21d
-2.6
Why this grade
Composite grade C. Momentum 92.2 / Value 57.4 / Sentiment 42.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-07-31. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$160.00
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$120.00
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$11.23B
Beta
1.13
Shares Out
63.49M
P/E (TTM)
6580.2
P/S (TTM)
13.47
P/FCF (TTM)
89.57
Rev YoY
+11.9%
EPS YoY
-66.4%
Gross Margin
+48.8%
Op Margin
+9.0%
Net Debt
-$77.68M
Current Ratio
9.05
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data